Publication
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (32)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 32
- cancerB Lymphoblastic Leukemia/Lymphomacivic_curation1.00
- cancerB Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Likecivic_curation1.00
- drugDasatinibcivic_curation1.00
- drugImatinibcivic_curation1.00
- drugRuxolitinibcivic_curation1.00
- geneABL1civic_curation1.00
- geneABL2civic_curation1.00
- geneCRLF2civic_curation1.00
- geneJAK2civic_curation1.00
- genePDGFRBcivic_curation1.00
- geneTYK2civic_curation1.00
- variantABL1 Fusioncivic_curation1.00
- variantABL1 Fusioncivic_curation1.00
- variantABL1 Fusioncivic_curation1.00
- variantABL1 Fusioncivic_curation1.00
- variantABL1 Fusioncivic_curation1.00
- variantABL2 Fusioncivic_curation1.00
- variantCRLF2 Fusioncivic_curation1.00
- variantCRLF2 Fusioncivic_curation1.00
- variantJAK2 Fusioncivic_curation1.00
- variantJAK2 Fusioncivic_curation1.00
- variantJAK2 Fusioncivic_curation1.00
- variantJAK2 Fusioncivic_curation1.00
- variantJAK2 Fusioncivic_curation1.00
- variantJAK2 Fusioncivic_curation1.00
- variantJAK2 Fusioncivic_curation1.00
- variantJAK2 Fusioncivic_curation1.00
- variantJAK2 Fusioncivic_curation1.00
- variantJAK2 Fusioncivic_curation1.00
- variantJAK2 Fusioncivic_curation1.00
- variantPDGFRB Fusioncivic_curation1.00
- variantTYK2 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (52)
50 items per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25207766
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KDM6A Fusion1 | ||||||||
| (diagnostic) | Childhood B-cell Acute Lymphoblastic LeukemiaUNRESOLVED | Diagnostic | C | Supports Positive | 2 | submitted | EID7255In a cohort of 264 patients with Ph-like B-ALL, one patient with a CRLF2 rearrangement had a PTK2B-KDM6A rearrangement. This fusion partner for PTK2B had not been previously reported. PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| STAG2 Fusion1 | ||||||||
| (diagnostic) | Childhood B-cell Acute Lymphoblastic LeukemiaUNRESOLVED | Diagnostic | C | Supports Positive | 2 | submitted | EID7256In a cohort of 264 patients with Ph-like B-ALL, one patient with a CRLF2 rearrangement had a PTK2B-STAG2 rearrangement. This fusion partner for PTK2B had not been previously reported. PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |